As shown in the tables below, there was a significant increase in the neurological event risk in the SAPIEN arm compared to Control, noting that the majority of Controls had BAV, in both the acute periprocedural period and the longer-term follow-up phase of the PARTNER trial. ❋ Larry Husten (2011)
Association of local IL-6 levels and periprocedural new ischemic lesions suggests that massive release from the plaque and entry into the cerebral circulation of IL-6 might be one of important factors on periprocedural complications related to CAS. ❋ Yuko Abe (2010)
Excessive anticoagulation increases risk of bleeding, whereas shortfalls raise the likelihood of periprocedural myocardial infarction, pulmonary embolism, and stroke. ❋ Unknown (2010)
During the periprocedural period, there was a higher risk of stroke with stenting and ❋ Brott (2010)
Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions ❋ Yuko Abe (2010)
The purpose of this study is to clarify whether inflammation factors are released from an atherosclerotic plaque after CAS and whether local release of inflammation factors is associated with periprocedural new ischemic lesions. ❋ Yuko Abe (2010)
The primary composite end point was stroke, myocardial infarction, or death from any cause during the periprocedural period or any ipsilateral stroke within 4 years after randomization. ❋ Brott (2010)
For one, investigators did not report the rate of periprocedural MI (by CK-MB or troponin) during their presentation, she notes. ❋ Unknown (2009)
-- There were no major periprocedural complications, and adverse events were similarly distributed between the ALD-201 and placebo groups. ❋ Unknown (2009)
At 30 days, the incidence of major adverse cardiac events was 20\% (2 patients had a periprocedural myocardial infarction; 2 patients died at days 12 and 14). ❋ Unknown (2009)
Among 624 patients with stable angina, ACS, or STEMI > 48 hours, those randomized to an under-two-hour infusion after successful PCI fared just as well as patients randomized to the standard 18-hour infusion in terms of periprocedural ischemic myocardial injury within 24 hours. ❋ Unknown (2009)
In response, Rodés-Cabau clarified that periprocedural MIs, defined as a CK-MB three times the upper limit of normal, occurred in just one patient in the stent group-hence, the 3\% mentioned in his concluding statements. ❋ Unknown (2009)
"Although there was a higher rate of adverse safety events in the intervention group than the control group, events in the intervention group were mainly a result of periprocedural complications," they wrote. ❋ Unknown (2009)
By 30 days, MACE rates were similarly reduced, driven entirely by the reduction in periprocedural MI. ❋ Unknown (2008)
Munich, Germany - Giving tirofiban (Aggrastat, Medicure Pharma) during elective PCI to patients who demonstrate aspirin and / or clopidogrel resistance can significantly reduce the risk of periprocedural MI, results from the ❋ Unknown (2008)
